Literature DB >> 20556454

Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice.

Corinne Fisher1, Sumeet Agrawal, Way Main Wong, Mike Fahie-Wilson, Bhaskar Dasgupta.   

Abstract

To study the source and clinical relevance of elevated cardiac troponin-T (cTnT) in patients with inflammatory myositis of varying etiology is the objective of this study. Patients with new-onset myositis of varying etiologies and raised serum cTnT and creatine kinase (CK) were identified. Clinical myocardial disease was ruled out on the basis of history, examination, ECG, and 2D-echocardiography. Along with serial estimation of CK levels, cTnT isoforms specific to myocardium (by electrochemiluminescence immunoassay) were used for serial estimation of cTnT levels. Gel-filtration chromatography was performed to investigate the nature of elevated cTnT in myositis patients compared to that in acute coronary syndrome (ACS). Patients requiring hospitalization due to an indication related to myositis were classified as having severe disease. All patients received conventional management for myositis as indicated in individual cases. Eleven patients (eight women, three men; aged 59-87 years) with polymyositis (five), dermatomyositis (three), statin-induced myopathy (two), and inclusion body myositis (one) were studied. The cTnT in myositis patients was found to be identical to cTnT in ACS. The time kinetics of cTnT was different from CK and their levels did not correlate. While CK normalized with treatment, cTnT levels exhibited prolonged elevation. Nine of the patients with raised cTnT had severe disease despite absence of clinical myocardial disease. Three died. cTnT in sera of patients with inflammatory muscle disease is of cardiac origin. It may identify a subgroup with subclinical myocardial involvement with differential response to treatment compared to skeletal muscle. We feel cTnT is an important laboratory investigation in patients with myositis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556454     DOI: 10.1007/s10067-010-1511-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

1.  Cardiac troponin T circulates in the free, intact form in patients with kidney failure.

Authors:  Michael N Fahie-Wilson; David J Carmichael; Michael P Delaney; Paul E Stevens; Elizabeth M Hall; Edmund J Lamb
Journal:  Clin Chem       Date:  2006-01-12       Impact factor: 8.327

Review 2.  Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB.

Authors:  F S Apple
Journal:  Clin Chim Acta       Date:  1999-06-30       Impact factor: 3.786

3.  Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle.

Authors:  M D McLaurin; F S Apple; E M Voss; C A Herzog; S W Sharkey
Journal:  Clin Chem       Date:  1997-06       Impact factor: 8.327

Review 4.  Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded.

Authors:  Allen Jeremias; C Michael Gibson
Journal:  Ann Intern Med       Date:  2005-05-03       Impact factor: 25.391

5.  Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim.

Authors:  V Ricchiuti; E M Voss; A Ney; M Odland; P A Anderson; F S Apple
Journal:  Clin Chem       Date:  1998-09       Impact factor: 8.327

6.  Cardiac troponin T in patients with clinically suspected myocarditis.

Authors:  B Lauer; C Niederau; U Kühl; M Schannwell; M Pauschinger; B E Strauer; H P Schultheiss
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

7.  Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes.

Authors:  Peter Ammann; Marco Maggiorini; Osmund Bertel; Edgar Haenseler; Helen I Joller-Jemelka; Erwin Oechslin; Elisabeth I Minder; Hans Rickli; Thomas Fehr
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094

8.  Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients.

Authors:  C E Denbow; J T Lie; R G Tancredi; T W Bunch
Journal:  Arthritis Rheum       Date:  1979-10

9.  Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.

Authors:  Gregory A Nichols; Carol E Koro
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

10.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

View more
  3 in total

1.  Is it cardiac involvement mimicking acute myocardial infarction in idiopathic inflammatory myopathy?

Authors:  Yizhi Xiao; Hui Luo; Shiqing Liu; Liping Duan; Yunhui You; Hongjun Zhao; Xiaoxia Zuo
Journal:  Exp Ther Med       Date:  2017-05-11       Impact factor: 2.447

2.  Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies.

Authors:  James B Lilleker; Axel C P Diederichsen; Søren Jacobsen; Mark Guy; Mark E Roberts; Jamie C Sergeant; Robert G Cooper; Louise P Diederichsen; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2018-06-01       Impact factor: 7.580

3.  Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study.

Authors:  Aleksandra Opinc; Joanna Sarnik; Olga Brzezińska; Marcin Makowski; Anna Lewandowska-Polak; Joanna Makowska
Journal:  Rheumatol Int       Date:  2020-03-28       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.